Top

Published in:

01-01-2017 | Original Article

Idiopathic Non-histaminergic Angioedema: Successful Treatment with Omalizumab in Five Patients

Authors: Charles Faisant, Aurélie Du Thanh, Catherine Mansard, Alban Deroux, Isabelle Boccon-Gibod, Laurence Bouillet

Published in: Journal of Clinical Immunology | Issue 1/2017

Abstract

Idiopathic non-histaminergic acquired angioedema (InH-AAE) is a rare disease characterized by AE resistant to antihistamines and a chronic course. We report five new cases of InH-AAE (two women and three men) with a rapid and dramatic response to the anti-immunoglobulin-E antibody omalizumab. In our literature review, we found 13 other relevant cases with a good response to this treatment. Overall, in 6 out of 18 patients, the doses of omalizumab required to prevent recurrences of attacks were higher than the licensed dose for chronic urticaria. No significant adverse effects have been reported.

Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol. 2005;53:373–88.CrossRefPubMed

Bork K. Angioedema. Immunol Allergy Clin N Am. 2014;34(1):23–31.CrossRef

Grattan C, Sabroe R, Greaves M. Chronic urticaria. J Am Acad Dermatol. 2002;46:645–57.CrossRefPubMed

Greaves MW. Pathology and classification of urticaria. Immunol Allergy Clin N Am. 2014;34(1):1–9. doi:10.1016/j.iac.2013.07.009.CrossRef

Greaves M. Chronic urticaria. J Allergy Clin Immunol. 2000;105(4):664–72.CrossRefPubMed

Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014.

Mansi M, Zanichelli A, Coerezza A, Suffritti C, Wu MA, Vacchini R, et al. Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients. J Intern Med. 2015;277(5):585–93.CrossRefPubMed

Zuberbier T, Aberer W, Asero R, BindslevJensen C, Brzoza Z, Canonica G, et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69:868–87.CrossRefPubMed

Maurer M, Rosen K, Hsieh H, Saini S, Grattan C, Gimenez-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–35.CrossRefPubMed

10.

Saini S, Rosen K, Hsieh H, Wong D, Conner E, Kaplan A, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128:567–573 e561.CrossRefPubMed

11.

Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali J, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic/ spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132:101–9.CrossRefPubMed

12.

Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol. 2003;3:311–7.CrossRefPubMed

13.

Colas C, Montoiro R, Fraj J, Garces M, Cubero JL, Caballero T. Nonhistaminergic idiopathic angioedema: clinical response to icatibant. J Investig Allergol Clin Immunol. 2012;22:520–1.PubMed

14.

Azofra J, Díaz C, Antépara I, Jaúregui I, Soriano A, Ferrer M. Positive response to omalizumab in patients with acquired idiopathic nonhistaminergic angioedema. Ann Allergy Asthma Immunol. 2015;114(5):418–9.e1.CrossRefPubMed

15.

Ozturk AB, Kocaturk E. Omalizumab in recurring larynx angioedema: a case report. Asia Pac Allergy. 2014;4(2):129–30.CrossRefPubMedPubMedCentral

16.

Sands MF, Blume JW, Schwartz SA. Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol. 2007;120(4):979–81.CrossRefPubMed

17.

Shroba J, Hanson J, Portnoy J. Current treatment options for idiopathic angioedema. Ann Allergy Asthma Immunol. 2015;115(5):429–33.CrossRefPubMed

18.

Wintenberger C, Boccon-Gibod I, Launay D, Fain O, Kanny G, Jeandel PY, et al. Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients. Clin Exp Immunol. 2014;178(1):112–7.CrossRefPubMedPubMedCentral

19.

Asero R, Tedeschi A, Cugno M. Heparin and tranexamic acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study. Int Arch Allergy Immunol. 2010;152:384–9.CrossRefPubMed

20.

Shedden C, Highet AS. Delayed pressure urticaria controlled by tranexamic acid. Clin Exp Dermatol. 2006;31(2):295–6.CrossRefPubMed

21.

von Websky A, Reich K, Steinkraus V, Breuer K. Complete remission of severe chronic recurrent angioedema of unknown cause with omalizumab. J Dtsch Dermatol Ges. 2013;11(7):677–8.CrossRef

22.

Muñoz JP, Casado AF, Taboada AC, Campos Muñoz L, Bran EL. Successful treatment of refractory idiopathic angioedema with omalizumab: review of the literature and function of IgE in angioedema. Clin Exp Dermatol. 2015.

23.

Faisant C, Boccon-Gibod I, Mansard C, Dumestre Perard C, Pralong P, Chatain C, et al. Idiopathic histaminergic angioedema without wheals: a case series of 31 patients. Clin Exp Immunol. 2016.

24.

Beck LA, Marcotto GV, MacGlashan Jr D, Togias A, Saini S. Omalizumab-induced reductions in mast cell FceRI expression and function. J Allergy Clin Immunol. 2004;114:527–30.CrossRefPubMed

25.

Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135(2):337–42.CrossRefPubMed

Title: Idiopathic Non-histaminergic Angioedema: Successful Treatment with Omalizumab in Five Patients
Authors: Charles Faisant
Aurélie Du Thanh
Catherine Mansard
Alban Deroux
Isabelle Boccon-Gibod
Laurence Bouillet
Publication date: 01-01-2017
Publisher: Springer US
Published in: Journal of Clinical Immunology / Issue 1/2017
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-016-0345-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Large Deletion of MAGT1 Gene in a Patient with Classic Kaposi Sarcoma, CD4 Lymphopenia, and EBV Infection

Postpartum HLA-Matched Bone Marrow Donation from Mother to Neonate for Reticular Dysgenesis

Low T Cell Numbers Resembling T−B+ SCID in a Patient with Wiskott–Aldrich Syndrome and the Outcome of Two Hematopoietic Stem Cell Transplantations

Newborn Screening for Severe Primary Immunodeficiency Diseases in Sweden—a 2-Year Pilot TREC and KREC Screening Study

Primary Immunodeficiency Classification on Smartphone

A CD57+ CTL Degranulation Assay Effectively Identifies Familial Hemophagocytic Lymphohistiocytosis Type 3 Patients

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials